Semma Therapeutics Inc, a company founded by the Harvard University Professor Douglas Melton, has raised $114 million in an oversubscribed Series B financing round to bring a stem cell therapy for Type1 diabetes into the clinic. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News
